Trial reportThe British journal of ophthalmology2023
Direct selective laser trabeculoplasty in open angle glaucoma study design: a multicentre, randomised, controlled, investigator-masked trial (GLAUrious).
Trial report in The British journal of ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Direct Selective Laser Trabeculoplasty (DSLT) In Open Angle Glaucoma (POAG): A Randomized Controlled Trial
A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Pressure (IOP) Reduction Without Medications at 6 Months in Naive, Untreated Glaucoma Patients
Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Intraocular Pressure in Non-Caucasian Open Angle Glaucoma Patients
Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Intraocular Pressure in Ocular Hypertension or Open-Angle Glaucoma Patients Previously Treated With Selective Laser Trabeculoplasty (SLT)
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Laser trabeculoplasty for open-angle glaucoma and ocular hypertension.The Cochrane database of systematic reviews · 2022Pooled it
- Clinical and Histopathological Evaluation of Maximal and Supramaximal Energy Direct Selective Laser Trabeculoplasty (DSLT): A Rabbit Model Safety Study.Lasers in surgery and medicine · 2026Article
- Direct selective laser trabeculoplasty in glaucoma: insights from the GLAUrious study.Annals of translational medicine · 2026Article
- Management and outcomes of primary open-angle glaucoma.Journal of family medicine and primary care · 2026Review
- Short-Term Stability of Retinal Nerve Fiber Layer and Ganglion Cell Layer Thickness Following Direct Selective Laser Trabeculoplasty in Patients with Ocular Hypertension and Glaucoma.Diagnostics (Basel, Switzerland) · 2026Article
- [Direct selective laser trabeculoplasty for glaucoma].Die Ophthalmologie · 2025Review
- Non-Contact Laser Therapy for Glaucoma: A Review of Direct Selective Laser Trabeculoplasty.Journal of clinical medicine · 2025Review
- First results of direct selective laser trabeculoplasty for the treatment of glaucoma.BMJ open ophthalmology · 2025Article
- Commentary on: Role of selective laser trabeculoplasty in India.Indian journal of ophthalmology · 2025Article
- Interventional glaucoma: Rethinking glaucoma treatment paradigms in the Asian context.Indian journal of ophthalmology · 2025Review
- Challenging glaucoma with emerging therapies: an overview of advancements against the silent thief of sight.Frontiers in medicine · 2025Review
- Providing capacity in glaucoma care using trained and accredited optometrists: A qualitative evaluation.Eye (London, England) · 2024Article
- Is selective laser trabeculoplasty shifting the glaucoma treatment paradigm in developing countries?The British journal of ophthalmology · 2022Article
- A Review of Selective Laser Trabeculoplasty: "The Hype Is Real".Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 9 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLaser trabeculoplasty is an effective and widely used treatment for glaucoma. A new laser technology, the Eagle direct selective laser trabeculoplasty (DSLT) device, may provide automated, fast, simple, safe and effective laser treatment for glaucoma in a broader range of clinical settings. This trial aims to test the hypothesis that translimbal DSLT is effective and not inferior to selective laser trabeculoplasty (SLT) in reducing intraocular pressure (IOP) in open angle glaucoma (OAG). METHODS AND ANALYSIS: This is a multicentre, randomised, controlled, investigator-masked study. The primary efficacy outcome is intergroup difference in mean change from baseline IOP measured at 6 months. Secondary outcomes include mean percentage reduction in IOP at 3, 6 and 12 months; proportion of participants with at least 20% reduction in IOP from baseline at 6 months; change in ocular hypotensive medications at 12 months and evaluation of safety. Participants were aged >= 40 years with OAG, including exfoliative or pigmentary glaucoma, or ocular hypertension with untreated or washed out IOP 22-35 mm Hg. TREATMENTS: DSLT: 120 shots, 3 ns, 400 µm spot size, energy 1.4-1.8 mJ delivered at the limbus over 2 s. SLT: approximately 100 shots, 3 ns, 400 µm spot size administered 360 degrees at the limbus using any gonioscopy lens, energy 0.3-2.6 mJ. A sample size of 164 is sufficient to detect a non-inferiority margin of 1.95 mm Hg for change from baseline IOP. CLINICAL TRIAL REGISTRATION NUMBER: NCT03750201, ISRCTN14033075.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.